Radioiodine in thyroid cancer—how to minimize side effects
Authors:
- Christoph ReinersCRChristoph Reiners
- Markus LusterMLMarkus Luster
- 19 June 2012
- journal article
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 9 (8) , 432-434
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid CancerNew England Journal of Medicine, 2012
- Radioiodine for Thyroid Cancer — Is Less More?New England Journal of Medicine, 2012
- Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid CancerNew England Journal of Medicine, 2012
- Radioiodine for remnant ablation and therapy of metastatic diseaseNature Reviews Endocrinology, 2011
- Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registryYearbook of Surgery, 2011
- No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2009
- Second Primary Malignancy Risk After Radioactive Iodine Treatment for Thyroid Cancer: A Systematic Review and Meta-analysisThyroid®, 2009
- Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.2006
- A Comparison of Short-Term Changes in Health-Related Quality of Life in Thyroid Carcinoma Patients Undergoing Diagnostic Evaluation with Recombinant Human Thyrotropin Compared with Thyroid Hormone WithdrawalThe Journal of Clinical Endocrinology & Metabolism, 2006
- Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled StudyThe Journal of Clinical Endocrinology & Metabolism, 2006